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ABSTRACT 
The aim of the present study was to develop a tablet formulation for sustained release of venlafaxine HCl. Control or sustain ed release 
formulations have great applications in improving the physicochemical properties and the pharmacokinetic profile of the drugs. Carbopol 
tablets containing venlafaxine HCl were developed successfully by wet granulation technique. The tablets were evaluated for matrix integrity 
and drug release in 0.1 N HCl using USP II dissolution apparatus maintained at optimum conditions. The developed tablets were robust and 
possessed excellent physicochemical properties. The tablets showed great matrix integrity and withstood the hydrodynamic environment of 
the dissolution medium for > 12 hours. The hydration and swelling behaviour of the tablets was excellent. It was found that the swelling 
characteristics of the tablets depended on the amount of the polymer used in the tablets as well as the polymer/drug ratio. The tablets provided 
more than 90% drug release over a period of 12 hours. The drug release data was subjected to kinetic dissolution modelling. It was found that 
the drug release from the tablets followed Korsmeyer-Peppas model of drug release. This suggests that the mechanism of the drug release from 
the formulations may be both diffusion as well as polymer erosion. 
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INTRODUCTION 
Drug treatment via the oral route is the most common and 
convenient way to administer medications (1). Due to its 
non-invasive nature, it can be regarded as cost efficient, 
highly acceptable to patients and thus compliance enhancing 
(2, 3). Sustained release (SR) drug delivery systems are 
developed to modulate the apparent absorption and/or alter 
the site of release of drugs, in order to achieve specific 
clinical objectives that cannot be achieved with conventional 
dosage forms (4, 5). Possible therapeutic benefits of a 
properly designed SR dosage form include improved efficacy 
and reduced adverse effects, increased convenience and 
patient compliance, optimized performance, a greater 
selectivity of activity or new indications. Drug release 
modification is a technique or approach by which the 
delivery pattern of a therapeutic agent is altered via 
engineering of physical, chemical and/or biological 
components into delivery systems for achieving 
desired/target plasma drug levels defined by the clinical 
pharmacology. 
Different polymers are used to impart sustained release 
characteristics to the formulations (6-8) e.g. hydroxypropyl 
methyl cellulose (HPMC), Eudragit, ethyl cellulose, carbopol 
etc. In the present study carbopol has been used a sustained 
release polymer for formulation development (9-11). 
Carbopol, a polyacrylic acid is a synthetic, high molecular 
weight, crosslinked polymer (12). It is readily absorbs water, 
hydrates and swells (13, 14). In addition, its hydrophilic and 
crosslinked nature makes it a potential candidate in 
controlled release drug delivery systems (15). In case of 
tablets formulated with carbopol polymer, the drug is 
trapped in the glassy core in dry state. It forms a gelatinous 
layer upon hydration. However, this gelatinous layer is 
significantly different structurally from the traditional matrix 
tablets. The hydrogel is not entangled chains of polymer, but 
discrete microgel made up of many polymer particles in 
which the drug is dispersed. The crosslinked network 
enables the entrapment of drug in the hydrogel domains. 
Since these hydrogels are not water soluble they do not 
dissolve, and erosion in the manner of linear polymer does 
not occur. Rather, when the hydrogel is fully hydrated, 
osmotic pressure from within works to break up the 
structure, essentially by sloughing off discrete pieces of the 
hydrogel. This hydrogel remains intact, and the drug 
continues to diffuse through the gel layer at a uniform rate. 
Venlafaxine HCl is an antidepressant of the serotonin-
norepinephrine reuptake inhibitor (SNRI) class first 
introduced by Wyeth in 1993 (16-19). Steady-state 
concentrations of venlafaxine and O-desmethylvenlafaxine 
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(20) in plasma are attained within 3 days of oral multiple 
dose therapy. Venlafaxine and O-desmethylvenlafaxine 
exhibited linear kinetics over the dose range of 75 to 450 
mg/day. Mean +/-SD steady-state plasma clearance of 
venlafaxine and O-desmethylvenlafaxine is 1.3 +/- 0.6 and 
0.4+/-0.2 L/hr/kg, respectively; apparent elimination half-
life is 5 +/- 2 and 11 +/- 2 hours, respectively; and apparent 
(steady-state) volume of distribution is 7.5 +/- 3.7 and 5.7 
+/- 1.8 L/kg, respectively. Venlafaxine and O-
desmethylvenlafaxine are minimally bound at therapeutic 
concentrations to plasma proteins (27% and 30%, 
respectively). 
 
Figure 1: Structure of Venlafaxine HCl 
MATERIALS AND METHODS 
Venlafaxine HCl was a kind gift from Sun Pharma India. 
Carbopol was kindly provided by Lubrizol India. All the other 
chemicals were of analytical grade. 
Preparation of Matrix Tablets 
Matrix tablets of venlafaxine HCl were prepared by wet 
granulation technique. All the ingredients were accurately 
weighed and thoroughly blended. The powder mixture of all 
the ingredients was then fed into the die cavity of the tablet 
machine which was compressed by 8 mm punch. The tablets 
were collected and stored in air tight polythene bags. The 
composition of various matrix tablets prepared is shown in 
table 1. 
Table 1: Composition of various sustained release 
tablets of Venlafaxine HCl 
Formulation Drug (mg) Polymer (mg) 
F1 50 400 
F2 50 300 
F3 50 200 
F4 50 100 
F5 50 50 
 
Weight variation and content uniformity 
Weight variation test was done on a batch of 20 tablets. The 
tablets were weighed individually and average weight of all 
the tablets was determined. The difference in the weight of 
all the tablets from the average weighed was calculated. 
Then the mean deviation of each tablet from the average 
weight was determined. 
Content uniformity test was conducted on 10 tablets. The 
tablets were dissolved in 0.1N HCl and the solution was 
filtered through Whtaman filter paper. Amount of drug in the 
solution was determined by UV spectrophotometric method 
at λmax 274 nm. 
Swelling Studies 
The tablets were immersed in 0.1 N HCl using USP II 
dissolution apparatus for 12 hours. The dimensions of the 
tablets at different intervals of time were measured using a 
Vernier caliper. Also the amount of water intake was 
determined by taking the difference of the initial and the 
final weights of the tablets at the start and the end of the 
experiment. 
Dissolution studies 
In vitro drug release was performed for the manufactured 
tablets of venlafaxine HCl according to the USP 30 
“Dissolution procedure” <711>, over a 12 hour period, using 
an automated dissolution system. A minimum of 6 tablets 
per batch were tested (N = 6). USP apparatus ӀӀ (paddle) was 
used at 50 rpm, with 900 ml dissolution medium (0.1N HCl) 
at 37°C; the UV absorbance of the dissolution medium was 
measured at different sampling time points. The release was 
calculated using a standard solution. The parameters set of in 
vitro dissolution testing of venlafaxine HCl and indomethacin 
matrix tablets is given in table 5 – 21. The conditions for 
dissolution studies of venlafaxine tablets are summarized in 
table 2. 
Table 2: Conditions for dissolution testing of carbopol 
tablets 
Parameter Venlafaxine HCl Matrix Tablets 
Condition 37 °C 
N 6 
Test period 12 hours 
Agitation rate 50 rpm 
Dissolution media 0.1N HCl 
Sampling time points 1, 2, 4, 6, 8, 12 hours 
Sinker JP basket sinker 
RESULTS AND DISCUSSION 
Polymer screening 
Before selecting a proper polymer for the development of 
matrix tablets of venlafaxine HCl a number of polymers 
possessing rate controlling properties were screened for 
best physicochemical properties. The polymers were 
screened on the basis of matrix integrity of the tablets and 
the drug release from the tablets. After evaluating a number 
of polymers like, HPMC, ethyl cellulose, eudragit etc. 
carbopol was found to impart the optimum properties to the 
sustained release tablets of venlafaxine HCl. 
Swelling Behaviour of Matrix Tablets 
The tablets of venlafaxine were placed in 900 ml of 0.1 N HCl 
in USP II dissolution apparatus stirring at a speed of 50 rpm 
and maintained at 37± 0.5 ºC. At different intervals of time 
the tablets were taken out and the dimensions of the tablets 
measured using a Vernier caliper. It was found that with 
time, the volume of the tablets increased largely (fig 2). It 
was found that the volume of the tablets was increased to 
more than double of the initial volume of the tablets. This 
may be attributed to the fact that carbopol undergoes rapid 
hydration when it comes in contact with water. As the water 
penetrates into the polymer matrix, it surrounds the 
individual polymeric chains, hydrates them and forms gel 
like structures. These gel like structures increase the 
dimensions of each polymer chain and hence the bulk of the 
tablet matrix increases. 
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Figure 2: Effect of amount of carbopol on swelling 
behaviour of tablets. With decrease in the amount of 
carbopol the swelling behaviour of tablets decreased 
Effect of Drug on Swelling Properties of Matrix Tablets 
Figure 3 shows the effect of drug on the swelling behaviour 
of the matrix tablets. It can be clearly seen from the graph 
shown that as the amount of the drug in the matrix tablets 
increases the hydration volume of the tablets decreases. This 
may be attributed to the fact that as the amount of the drug 
in the tablets increases a large proportion of the polymer is 
replaced by the drug. Hence the decrease in the amount of 
the polymer decreased the volume of hydration and the 
amount of swelling. Further, since the drug dissolution 
results in the leaching out of the drug from the polymer 
matrix, which results in incorporation of voids inside the 
matrix and hence decreases the net contents of the tablet 
resulting in decreased swelling. 
 
Figure 3: Effect of amount of drug on hydration volume 
of carbopol tablets. With increase in the amount odrug 
the hydration volume decreased 
Polymer:Drug Ratio and Integrity of Tablets 
Tablets containing different amounts of polymer and drug 
were evaluated for matrix integrity. The tablets were placed 
in 900 ml of 0.1N HCl in USP II apparatus stirring at a speed 
of 50 rpm and maintained at 37± 0.5 ºC  for 12 hours and the 
effect on the matrix integrity was observed up to  12 hours. It 
was found that that as the polymer to drug ratio decreased 
the matrix integrity of the tablets also decreased. This is 
because of the fact that the polymeric chains in the carbopol 
matrices are chemically crosslinked and as the amount of the 
polymer in the tablets decreases the amount of crosslinking 
also decrease resulting in lowered matrix integrity. Figure 4 
shows the effect of the polymer:drug ratio on the matrix  
integrity of the tablets. 
 
Figure 4: Effect of Polymer/Drug Ratio on matrix 
integrity of carbopol tablets. With decrease in 
polymer/drug ratio, matrix integrity of carbopol tablets 
decreased. 
Drug Release Studies 
The carbopol tablets were evaluated for drug release studies 
using a USP II apparatus. The tablets were placed in 900 ml 
of 0.1 N HCl maintained at 37± 0.5 ºC and with the paddles 
stirring at a rate of 50 rpm. The drug release profile of the 
carbopol tablets containing venlafaxine is shown in table 3 
and Figure 5. Among the various formulations prepared, F2 
and F3 showed the better results. The matrix integrity as 
well as the drug release was excellent. The tablets withstood 
the hydrodynamic conditions of the dissolution medium up 
to 12 hours and the drug release from the formulation was > 
90%. 
Table 3: %Cumulative drug release from carbopol 
tablets 
Time (hrs) F2 F3 
1 18.65 19.32 
2 27.89 29.75 
3 37.49 37.95 
4 43.5 44.37 
5 50.46 55.74 
6 59.72 63.41 
7 64.13 68.58 
8 68.83 76.03 
9 75.4 81.63 
10 82.73 87.44 
11 87.55 92.89 
12 92.51 96.77 
 
 
Figure 5: Graphical representation of the drug release 
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Dissolution Data Modelling 
Dissolution modelling is very important in providing the idea 
about the kinetics of the drug release from a dosage form. 
The drug release obtained from the formulations F2 and F3 
were subjected to dissolution data modelling in order to 
derive the basic underlying mechanism of drug release from 
the tablets. The outlook of the various models applied to the 
drug release is provided in table 4 below. 
 
Table 4: Regression values obtained from various dissolution data models 
Model  Zero Order First Order Higuchi Korsmeyer-Peppas 
R² Value F1 0.9916 0.9385 0.9624 0.9983 
 F2 0.9871 0.9105 0.9683 0.9975 
 
It was found that the tablet formulations mentioned above 
followed Korsmeyer-Peppas model of drug release since the 
regression values for the model among the all other models 
was highest close to 1 (R2=0. 9983). Hence it can be 
concluded that according to the given model the drug from 
the tablet formulations is released by a combination of more 
than one mechanism, i.e. diffusion and polymer erosion. The 
various models are shown in figure 6. 
 
 
Figure 6: Various dissolution data models showing kinetics of drug release a) Zero Order model; b) First Order model; 
c) Higuchi model; d) Korsmeyer-Peppas model 
 
Weight variation and content uniformity 
The average weight of the formulations tested was found to 
be within the permissible limits as shown in table 5. The 
test was carried on 20 tablets and all the tablets passed the 
test. 
Table 5: Weight variation of sustained release tablets 
Formulation Tablets Average  Wt. 
F1 20 361 ± 8 
F2 20 259 ± 9 
 
The uniformity in the amount of drug in all the formulations 
prepared was evaluated by content uniformity test. This test 
was conducted on 10 tablets. The variation in the amount of 
the drug in different tablets of a batch was within the 
permissible limits. Table 6 shows content uniformity of the 
tablet formulations. 
  
Table 6: Drug content uniformity of sustained release 
tablets 
Formulation Tablets Average  Drug Content 
F1 10 50 ± 2 
F2 10 50 ± 3 
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CONCLUSION 
A large number of polymers are being investigated for the 
development of sustained drug delivery systems. These 
dosage forms ensure constant delivery of drugs to the site of 
absorption and as a result improve the pharmacokinetics of 
drugs. In the present study sustained dosage form of 
venlafaxine HCl using carbopol as rate controlling polymer 
has been developed. It has been clearly shown that carbopol 
tablets of venlafaxine HCl can be efficiently prepared by wet 
granulation technique. The developed tablets possessed 
excellent physicochemical properties and provided drug 
release of >90% over a period of 12 hours at a constant rate. 
The tablets displayed great matrix integrity for the whole 
time of experiment (i.e. >12 hours). Hence the above 
developed tablets can be beneficial in providing constant 
drug to the site of absorption and thus increasing the 
bioavailability of the drug, venlafaxine HCl. 
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